Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy
Withdrawn
- Conditions
- Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy
- Interventions
- Other: Genotyping
- Registration Number
- NCT01867203
- Lead Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Brief Summary
Patients needing lipid lowering therapy will be recruited before initiation of the treatment. For each patient, total and LDL cholesterol levels before start of therapy will be measured. One, three and six months after his/her first visit, when steady-state will be reached, for each included patient, the cholesterol levels will be re-assessed in order to evaluate the response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is to assess the association between patient's genotype and the response to statin therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patient known to be compliant
- Age [25-80]
- treated with Atorvastatin, simvastatin, fluvastatin.
Exclusion Criteria
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Statin users Genotyping -
- Primary Outcome Measures
Name Time Method Cholesterol levels-side effects 1 to 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Saint-Luc Hospital
🇧🇪Brussels, Belgium